Every open market buy and sale of Recursion Pharmaceuticals, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $7.4M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when RXRX insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an RXRX officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every RXRX insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Blake BorgesonDirector | Sale plan | 40,000 | $3.88 | $155K | 6,068,287 | Nov 4Form 4 |
| Oct 6, 2026 | Robert HershbergDirector | Sale plan | 25,000 | $5.00 | $125K | 162,156 | Oct 7Form 4 |
| Oct 6, 2026 | Blake BorgesonDirector | Sale plan | 50,000 | $4.84 | $242K | 6,108,287 | Oct 7Form 4 |
| Sep 8, 2026 | Najat KhanCEO and President | Sale plan | 22,408 | $3.52 | $79K | 2,072,890 | Sep 10Form 4 |
| Sep 1, 2026 | Blake BorgesonDirector | Sale plan | 30,000 | $3.34 | $100K | 6,158,287 | Sep 2Form 4 |
| Aug 4, 2026 | Blake BorgesonDirector | Sale plan | 30,000 | $3.25 | $98K | 6,188,287 | Aug 6Form 4 |
| Jul 7, 2026 | Blake BorgesonDirector | Sale plan | 40,000 | $3.96 | $159K | 6,218,287 | Jul 9Form 4 |
| Jun 18, 2026 | Namandje BumpusDirector | Sale plan | 3,963 | $3.18 | $13K | 127,632 | Jun 22Form 4 |
| Jun 5, 2026 | Christopher GibsonDirector | Sale plan | 40,000 | $3.62 | $145K | 883,735 | Jun 5Form 4 |
| Jun 5, 2026 | Najat KhanCEO and President | Sale plan | 23,588 | $3.58 | $84K | 2,175,796 | Jun 5Form 4 |
| Jun 3, 2026 | Namandje BumpusDirector | Sale plan | 4,386 | $3.54 | $16K | 43,171 | Jun 4Form 4 |
| Jun 2, 2026 | Blake BorgesonDirector | Sale plan | 30,000 | $3.68 | $110K | 6,169,863 | Jun 4Form 4 |
| May 22, 2026 | Christopher GibsonDirector | Sale plan | 40,000 | $3.08 | $123K | 883,735 | May 27Form 4 |
| May 7, 2026 | Christopher GibsonDirector | Sale plan | 40,000 | $3.37 | $135K | 926,556 | May 8Form 4 |
| May 5, 2026 | Blake BorgesonDirector | Sale plan | 30,000 | $3.52 | $106K | 6,199,863 | May 7Form 4 |
RXRX insider trading FAQ
Are RXRX insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of RXRX on the open market in 0 trades, and 6 sold $7.4M in 34 trades, 100% of that under pre-arranged trading plans.
When did an RXRX insider last buy shares?
There has been no open market insider purchase of RXRX in the last two years.
When did an RXRX insider last sell shares?
Blake Borgeson (Director) sold 40,000 shares for $155K on Nov 3, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
